Showing results (441-450 of 6,499) with videos related to
Sort By:
Pageof 650
Cancer Immunology, Immunotherapy : CII|March 21, 2018
The novel deubiquitinase inhibitor b-AP15 induces direct and NK cell-mediated antitumor effects in human mantle cell lymphomaKorbinian N Kropp, Stefanie Maurer, Kathrin Rothfelder, et al.Cancer Immunology, Immunotherapy : CII|March 7, 2018
T-cell receptor-β V and J usage, in combination with particular HLA class I and class II alleles, correlates with cancer survival patternsBlake M Callahan, John M Yavorski, Yaping N Tu, et al.Cancer Immunology, Immunotherapy : CII|March 7, 2018
CD137L dendritic cells induce potent response against cancer-associated viruses and polarize human CD8+ T cells to Tc1 phenotypeBhushan Dharmadhikari, Emily Nickles, Zulkarnain Harfuddin, et al.Cancer Immunology, Immunotherapy : CII|January 1, 1987
Lysis of autologous tumor cells by blood lymphocytes activated in autologous mixed lymphocyte tumor cell culture--no correlation with the postsurgical clinical courseF Vánky, E Klein, J Willems, et al.Cancer Immunology, Immunotherapy : CII|March 9, 2018
Rituximab as a therapeutic option for patients with advanced melanomaJulia K Winkler, Matthias Schiller, Carolin Bender, et al.Cancer Immunology, Immunotherapy : CII|March 10, 2018
Cancer immunotherapy in patients with brain metastasesSalvatore Caponnetto, Arianna Draghi, Troels Holz Borch, et al.Cancer Immunology, Immunotherapy : CII|January 1, 1986
Rejection of reovirus-treated L1210 leukemia cells by miceM E Williams, D C Cox, J R StevensonCancer Immunology, Immunotherapy : CII|August 4, 2017
An unbiased in vivo functional genomics screening approach in mice identifies novel tumor cell-based regulators of immune rejectionCasey W Shuptrine, Reham Ajina, Elana J Fertig, et al.Cancer Immunology, Immunotherapy : CII|March 4, 2018
Impaired lymphocyte function in patients with hepatic malignancies after selective internal radiotherapyAglaia Domouchtsidou, Vahé Barsegian, Stefan P Mueller, et al.Cancer Immunology, Immunotherapy : CII|March 4, 2018
Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditionsNiken M Mahaweni, Gerard M J Bos, Constantine S Mitsiades, et al.Pageof 650